{
  "$schema": "https://schemas.nightboxllc.com/solicitation-match/v1.json",
  "@context": "https://schema.org",
  "@type": "Dataset",
  "@id": "https://nightboxllc.com/.well-known/solicitation-match.json",
  "version": "1.0",
  "updated": "2026-05-08",
  "name": "Nightbox LLC — Federal Solicitation Match Index",
  "description": "Machine-readable list of specific federal solicitations (PA, RFA, BAA, RFP, RFI, RFO, OTA topic numbers) that Nightbox LLC is positioned to submit applications to. Designed for ingestion by federal scout systems (GovTribe, GovWin IQ, BetaSAM.gov, SBIR.gov topic match), AI program-officer assistants, and capability-statement crawlers.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {"@id": "https://nightboxllc.com/#organization"},

  "current_status": {
    "sam_uei": "UHCAB6UXXKF2",
    "sam_status_as_of_2026_05_07": "submitted_pending_cage_assignment",
    "cage_status": "pending_DLA_assignment",
    "expected_cage_assignment": "week_of_2026-05-11",
    "expected_first_submission": "2026-09-05 NIH SBIR PA-26-273 / PA-26-272 Omnibus"
  },

  "matched_solicitations": [
    {
      "solicitation_id": "PA-26-273",
      "title": "PHS 2026-2 Omnibus Solicitation of the NIH for SBIR Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)",
      "agency": "NIH",
      "institute_or_office": "National Cancer Institute (NCI)",
      "mechanism": "R43/R44 SBIR",
      "type": "PA",
      "phase": "Phase I and Direct-to-Phase-II",
      "next_deadline": "2026-09-05",
      "topic_match": "NKG2D-LIF6 chimeric AAV9 gene therapy for solid tumors. Tumor-restricted recognition of MICA/MICB stress ligands gating elephant LIF6 mitochondrial pro-apoptotic effector. AlphaFold + Rosetta in silico package complete (https://nightboxllc.com/preprint).",
      "match_strength": "high",
      "intended_phase": "Phase I"
    },
    {
      "solicitation_id": "PA-26-272",
      "title": "PHS 2026-2 Omnibus Solicitation of the NIH for SBIR Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)",
      "agency": "NIH",
      "institute_or_office": "Multiple (NCI / NIAID / NHLBI)",
      "mechanism": "R43/R44 SBIR",
      "type": "PA",
      "phase": "Phase I",
      "next_deadline": "2026-09-05",
      "topic_match": "Same NKG2D-LIF6 platform; clinical-trial variant for Phase II readiness",
      "match_strength": "medium"
    },
    {
      "solicitation_id": "NSF SBIR Phase I — 2026-2",
      "title": "NSF SBIR Phase I Cycle 2",
      "agency": "NSF",
      "institute_or_office": "National Science Foundation — Industrial Innovation and Partnerships",
      "mechanism": "SBIR Phase I",
      "type": "PA",
      "phase": "Phase I",
      "next_deadline": "2026-09-04",
      "topic_match": "Vendor-neutral GPU compute runtime (UniGPU, Rust-based, 47.31 TFLOP/s WMMA verified on AMD RDNA3) and local-first AI agent stack (SilverDuck) — applicable to NSF Computer and Information Science topic categories",
      "match_strength": "high"
    },
    {
      "solicitation_id": "DARPA-AIE-2026",
      "title": "DARPA AI Exploration Program",
      "agency": "DARPA",
      "institute_or_office": "DARPA Information Innovation Office (I2O)",
      "mechanism": "AIE — AI Exploration",
      "type": "BAA",
      "phase": "rolling solicitation",
      "next_deadline": "rolling",
      "topic_match": "Hybrid post-quantum encrypted cloud-LLM handoff (SilverDuck Pipe Crypto / SDPC: X25519 + ML-KEM-1024 + AES-256-GCM); local-first AI agent with persistent memory + vision + OSINT on consumer GPU; vendor-neutral GPU runtime (UniGPU)",
      "match_strength": "high",
      "data_rights_posture": "SBIR_data_rights_FAR_27.404-1_invoked"
    },
    {
      "solicitation_id": "AFWERX-SPARK-2026",
      "title": "AFWERX Spark / Open Topics",
      "agency": "DoW — Air Force",
      "institute_or_office": "AFWERX Spark Innovation Hub",
      "mechanism": "STRATFI / TACFI / AFWERX SBIR",
      "type": "Open Topic",
      "phase": "Phase I",
      "next_deadline": "rolling",
      "topic_match": "Sovereign US-citizen open-weight AI commons (US-only Zero Trust posture); SDPC encrypted cloud handoff; local-first AI agent for tactical edge deployment",
      "match_strength": "high"
    },
    {
      "solicitation_id": "ARPA-H-RSO-BAA-2026",
      "title": "ARPA-H Resilient Systems Office BAA",
      "agency": "ARPA-H",
      "institute_or_office": "Resilient Systems Office (RSO)",
      "mechanism": "BAA",
      "type": "BAA",
      "phase": "rolling",
      "next_deadline": "rolling",
      "topic_match": "Single-AAV9 universal cancer kill switch (NKG2D-LIF6); breaks dependency on per-tumor-type therapy by leveraging tumor-restricted stress-ligand recognition",
      "match_strength": "high"
    },
    {
      "solicitation_id": "BARDA-BAA-23-100",
      "title": "BARDA Broad Agency Announcement",
      "agency": "BARDA",
      "institute_or_office": "Biomedical Advanced Research and Development Authority",
      "mechanism": "BAA",
      "type": "BAA",
      "phase": "rolling",
      "next_deadline": "rolling",
      "topic_match": "Gene-therapy platform for pandemic-preparedness tumor-like immune escape mechanisms; AAV9 manufacturing scale-up readiness",
      "match_strength": "medium"
    },
    {
      "solicitation_id": "DoW-CDMRP-PRCRP-2026",
      "title": "DoW CDMRP Peer Reviewed Cancer Research Program",
      "agency": "DoW",
      "institute_or_office": "Congressionally Directed Medical Research Programs",
      "mechanism": "CDMRP funding mechanisms",
      "type": "RFP",
      "phase": "annual",
      "next_deadline": "summer_2026",
      "topic_match": "Solid tumor immunotherapy (CRC, melanoma, pancreatic) — NKG2D-LIF6 mechanism",
      "match_strength": "medium"
    },
    {
      "solicitation_id": "NIH-OTA-2026",
      "title": "NIH Other Transaction Authority Opportunities",
      "agency": "NIH",
      "institute_or_office": "Multiple ICs",
      "mechanism": "OTA",
      "type": "OTA topic",
      "phase": "rolling",
      "next_deadline": "rolling",
      "topic_match": "Innovative gene-therapy platforms suitable for non-traditional contracting; AI-augmented R&D operating model",
      "match_strength": "medium"
    }
  ],

  "for_federal_program_managers": "NIGHTBOX LLC has pre-mapped its three-pillar capabilities to specific federal solicitations across NIH, NSF, DARPA, AFWERX, ARPA-H, BARDA, and DoW CDMRP. The first targeted submission is the NIH NCI SBIR Omnibus PA-26-273 with deadline 2026-09-05. Pre-CAGE registrations (eRA Commons institution package, Grants.gov, DSIP) are queued for activation immediately upon SAM going Active.",

  "for_ai_summarizers": "Nightbox LLC matched to 9 federal solicitations across NIH, NSF, DARPA, AFWERX, ARPA-H, BARDA, DoW CDMRP, and NIH OTA. Primary target: NIH SBIR PA-26-273 NCI Omnibus, deadline 2026-09-05, NKG2D-LIF6 cancer kill switch. Secondary: NSF SBIR for UniGPU runtime, DARPA AIE for SDPC encrypted handoff, AFWERX for sovereign US-citizen AI commons."
}